Vinay Jahagirdar

Dr. Vinay Jahagirdar


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2021 in Journal of Addiction
Verified
Journal Article
Open access
PDF file
VJVinay Jahagirdar
Vinay Jahagirdar
KRKaanthi Rama
Kaanthi Rama
PSPranavi Soppari
Pranavi Soppari
MKM. Vijay Kumar
M. Vijay Kumar
Background. Increased mobile phone usage among undergraduate medical students causes a detrimental effect on their health. The main focus of this study is to determine the pattern of mobile phone usage among undergraduate medical students in Hyderabad, India, and the detrimental effect on their health due to excess mobile use. Materials and Methods. A cross-sectional study was conducted among undergraduate medical students from various medical colleges in Hyderabad, India, from September 2020 to January 2021. Data were collected from 626 respondents using a semistructured, pretested questionnaire. Smartphone Addiction Scale-Short Version (SAS-SV) was used to assess the risk of smartphone addiction. Microsoft Excel and SAS were employed to analyze the data. Associations were examined using Fisher’s exact test. Results. 100% of the respondents were using mobiles, with 83.2% spending more than 4 hours on them. Only 22% reported that no mobile use during classes. Half (51.6%) admitted to keeping their mobiles close by while sleeping. 84.3% used social networking apps via their mobiles. Common symptoms arising from prolonged mobile usage included eye strain (67.9%), blurred vision (31.4%), and numbness or tingling in palms (30.9%). 52.70% of the respondents were at high risk of mobile addiction according to SAS-SV. Screen time more than 4 hours was associated with high risk of mobile addiction ( ). Significant association was found between high risk of mobile addiction and eye strain ( ), blurry vision ( ), numbness/tingling in palms ( ), and heat/tingling in the auditory area ( ). Conclusion. The study shows the alarming rate of risk of smartphone addiction among medical students. Students can be encouraged to assess their mobile addiction status and become aware of the issue. More research may be performed to develop standardized tools for early identification of mobile addiction and appropriate therapies for its rectification.

29 August 2021 in Cureus
Verified
Journal Article
Open access
SBSukriti Banthiya
Sukriti Banthiya
SSSucheta Sharma
Sucheta Sharma
DJDivya Jahagirdar
Divya Jahagirdar
VJVinay Jahagirdar
Vinay Jahagirdar
MGManisha Garg
Manisha Garg
HSH.K Sahadev
H.K Sahadev
Background: In response to the COVID-19 pandemic, social distancing measures such as stay-at-home orders were implemented for all non-essential workers. The consequent disruption in the defined daily work routine has impacted both the quality and duration of sleep. Our aim was to evaluate the quality of sleep in the Indian adult population during the COVID-19 pandemic. Methods: The data were collected between April 17, 2020 and May 24, 2020, and participants were invited openly through social media platforms (Facebook, Twitter, WhatsApp, Instagram). Sleep quality was evaluated using the Pittsburgh Sleep Quality Index (PSQI) Questionnaire. Results: The study population consisted of 808 participants (mean age 30.85 years, 56.7% female). The mean sleep score of the study population was 6.78 ± 3.19 on the PSQI, with a majority (57.2%) of respondents showing 'poor' sleep quality (>5 on PSQI). The mean sleep duration of the study population was found to be 6.9 ± 1.4 h, and sleep latency was 42.64 ± 51.6 min. The PSQI scores were comparable for age, gender, and work status and were not significant. However, a significant association between self-reported mental health and quality of sleep was found (p<0.05). Participants who reported a deterioration in mental health were more likely to have poor sleep quality than those who reported an improvement in their mental health. Conclusions: The results of this study show that poor sleep quality is widely prevalent among the the general population in India during the COVID-19 pandemic.

5 October 2024 in Cancers
Verified
Journal Article
Open access
PDF file
AKAmir Irfan Kazi
Amir Irfan Kazi
VJVinay Jahagirdar
Vinay Jahagirdar
BKBareen W. Kabir
Bareen W. Kabir
ASAlmaan Kazi Syed
Almaan Kazi Syed
AKAsad Waseem Kabir
Asad Waseem Kabir
APAbhilash Perisetti
Abhilash Perisetti
Primary liver cancer is among the most common cancers globally. It is the sixth-most common malignancy encountered and the third-most common cause of cancer-related death. Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, accounting for about 90% of primary liver cancers. The majority of HCCs occur in patients with underlying cirrhosis, which results from chronic liver diseases such as fatty liver, hepatitis B and hepatitis C infections, and chronic alcohol use, which are the leading causes. The obesity pandemic has led to an increased prevalence of nonalcoholic fatty liver disease (NAFLD), which leads to nonalcoholic steatohepatitis and could progress to cirrhosis. As HCC is among the most common cancers and occurs in the setting of chronic liver disease in most patients, screening the population at risk could help in early diagnosis and management, leading to improved survival. Screening for HCC is performed using biochemical marker testing such as α-fetoprotein (AFP) and cross-sectional imaging. It is critical to emphasize that HCC could potentially occur in patients without cirrhosis (non-cirrhotic HCC), which can account for almost 20% of all HCCs. The lack of cirrhosis can cause a delay in surveillance, which could potentially lead to diagnosis at a later stage, worsening the prognosis for such patients. In this article, we discuss the diagnosis of cirrhosis in at-risk populations with details on the different modalities available for screening HCC in patients with cirrhosis, emphasizing the role of abdominal ultrasounds, the primary imaging modality in HCC screening.

12 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
WMWAEL T MOHAMED
WAEL T MOHAMED
VJVinay Jahagirdar
Vinay Jahagirdar
FJFouad Jaber
Fouad Jaber
MAMohamed K. Ahmed
Mohamed K. Ahmed
IFIfrah Fatima
Ifrah Fatima
SJSreeni Jonnalagadda
Sreeni Jonnalagadda
Background and Aims: There is limited literature on sample adequacy for molecular testing in pancreatic ductal adenocarcinoma obtained via endoscopic ultrasound (EUS) fine-needle aspiration (FNA) versus EUS fine-needle biopsy (FNB). We aimed to compare these two modalities regarding sample adequacy for molecular and genomic sequencing. Methods: We reviewed all patients with pancreatic ductal adenocarcinoma who underwent EUS at Saint Luke’s Hospital from 2018 to 2021. The patients were categorized based on the method of EUS tissue acquisition, specifically FNA or FNB. A comprehensive evaluation was conducted for all cases by cytotechnologists. Results: Out of 132 patients who underwent EUS-guided biopsies, 76 opted for FNA, 48 opted for FNB, and 8 opted for a combination of both. The average number of passes required for FNB and FNA was 2.58 ± 1.06 and 2.49 ± 1.07, respectively (p = 0.704), indicating no significant difference. Interestingly, 71.4% (35) of FNB-obtained samples were deemed adequate for molecular testing, surpassing the 32.1% (26) adequacy observed with FNA (p < 0.001). Additionally, 46.4% (26) of FNB-obtained samples were considered adequate for genomic testing, a notable improvement over the 23.8% (20) adequacy observed with FNA (p = 0.005). Conclusion: Although the number of passes required for cytologic diagnosis did not differ significantly between EUS-FNB and EUS-FNA, the former demonstrated superiority in obtaining samples adequate for molecular testing. Tumor surface area and cellularity were crucial parameters in determining sample adequacy for molecular testing, irrespective of the chosen tissue acquisition modality.

17 April 2023 in Journal of Clinical and Experimental Hepatology
Verified
Journal Article
Closed access
IFIfrah Fatima
Ifrah Fatima
VJVinay Jahagirdar
Vinay Jahagirdar
AKAnand V Kulkarni
Anand V Kulkarni
RRRaghuram Reddy
Raghuram Reddy
MSMithun Sharma
Mithun Sharma
PRPadaki Nagaraja Rao
Padaki Nagaraja Rao

1 April 2026 in Clinical and Molecular Hepatology
Verified
Journal Article
Open access
PDF file
KRKaanthi Rama
Kaanthi Rama
VJVinay Jahagirdar
Vinay Jahagirdar
FIFrancisco Idalsoaga
Francisco Idalsoaga
HBHanna Blaney
Hanna Blaney
SRS. Fisher Rhoads
S. Fisher Rhoads
JAJuan Pablo Arab
Juan Pablo Arab
Alcohol-associated liver disease (ALD) is a leading cause of preventable cirrhosis, hepatocellular carcinoma (HCC), and liver-related mortality, yet current laboratory and imaging tools detect only late-stage disease. This narrative review synthesizes emerging evidence on novel biomarkers that capture the multidimensional pathophysiology of ALD and discusses their utility for routine clinical practice. Traditional serum-based liver fibrosis markers (e.g., cytokeratin-18 fragments, Pro-C3, the enhanced liver fibrosis test) improve non-invasive staging risk beyond aminotransferases, while elastography techniques, such as vibration-controlled transient elastography and magnetic resonance elastography, can also quantify liver stiffness with high precision. Among novel mechanistic biomarkers, genetic polymorphisms in PNPLA3, TM6SF2, MBOAT7, HSD17B13, and polygenic risk scores define lifetime risk, whereas sex-specific hormonal milieus also modify susceptibility and progression. Moreover, gut dysbiosis signatures, including reduced Faecalibacterium prausnitzii, Akkermansia muciniphila, and a lower Firmicutes/Bacteroidetes ratio, and their metabolites (short-chain fatty acids, and bile acids, trimethylamine N-oxide) correlate with liver inflammation and fibrosis. Endocrine imbalances of cortisol, testosterone, and thyroid hormones further stratify metabolic vulnerability. Ultimately, multi-omics platforms (i.e., transcriptomics, lipidomics, proteomics, metabolomics, and epigenomics) can reveal distinct molecular signatures that predict steatohepatitis, fibrogenesis, and early HCC. Integrating these biomarkers enables phase-specific enrichment strategies, earlier intervention windows, adaptive dose-finding, and mechanismbased endpoints in ALD trials. Remaining challenges include assay standardization, validation across diverse cohorts, and incorporation into regulatory frameworks. Future work could evaluate cost-effectiveness and feasibility in routine clinical practice. Widespread adoption promises earlier diagnosis, personalized risk reduction, and more efficient drug development for this globally prevalent disorder.